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Abstract
Background: MicroRNAs (miRs) are an abundant class of small non-coding RNAs (~22 nt) that reprogram gene ex-
pression by targeting mRNA degradation and translational disruption. An emerging concept implicates miR coup-
ling with transcription factors in myeloid cell development and function, thus contributing to host defense and
inflammation. The important role that these molecules play in the pathogenesis of HIV-1 is only now emerging.
Results: We provide evidence that exposure of monocyte-derived dendritic cells (MDDCs) to recombinant HIV-1 R5
gp120, but not to CCR5 natural ligand CCL4, influences the expression of a panel of miRs (i.e., miR-21, miR-155 and
miR-181b) regulated by STAT3 and potentially targeting genes belonging to the STAT3 signaling pathway. The
blockage of gp120-induced STAT3 activation impairs gp120 capacity to modulate the expression level of above
mentioned miRs. Predictive analysis of miR putative targets emphasizes that these miRs share common target
genes. Furthermore, gene ontology and pathway enrichment analysis outline that these genes mainly belong to
biological processes related to regulation of transcription, in a complex network of interactions involving pathways
relevant to HIV-DC interaction.
Conclusions: Overall, these results point to gp120-triggered modulation of miR expression via STAT3 activation as a
novel molecular mechanism exploited by HIV-1 to affect DC biology and thus modulate the immune response
through complex regulatory loops involving, at the same time, miRs and transcription factors.
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Background
MicroRNAs (miRs) are an abundant class of small non-
coding RNAs (~22 nt) that function to control gene ex-
pression and restrict viral replication in host cells [1, 2].
Dysregulation of miRs expression is associated with nu-
merous disease states. The human genome encodes hun-
dreds of miRs with the potential to regulate up to 92 %
of genes, mostly through inhibition of translation and/or
promotion of mRNA degradation. Growing evidence in-
dicates that miRs and transcription factors can jointly
regulate target gene expression in the form of feed-
forward or feedback loops [3]. These regulatory loops
serve as important motifs in functional networks and
play critical roles in multiple biological processes, either in
healthy states or diseases. miR-mediated gene silencing
has been shown to be a key event in viral pathogenesis
[4–6]. Several cellular miRs show substantial changes in
expression upon HIV-1 infection [6, 7], and contributes to
viral latency in primary CD4+ T lymphocytes [8]. HIV-1
infectivity has been reported to be influenced by cellular
miRs [9]. Multiple cellular miRs can modulate both viral
infectivity and replication by targeting directly the viral
genome or decreasing the expression of host proteins re-
quired for virus replication [1]. More recently, changes in
miRs expression profile of CD4+ T lymphocytes after ex-
posure to HIV-1 allowed to discriminate among different
stages of HIV infection [10].
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Dendritic cells (DCs) are professional antigen presenting
cells playing a critical role in the orchestration and fine-
tuning of the immune response [11]. At the mucosal sites,
they are primary targets of HIV-1 infection, co-opted by
the virus to facilitate its transfer to T lymphocyte and
body dissemination [12]. However, how HIV-1 manipu-
lates DC biology to use these cells to its own advantage
without marked cytopathic effects is still unclear. In these
cells, the interaction of the envelope protein gp120 with
surface receptors triggers early signaling events even in
the absence of productive infection and may profoundly
influence cellular behavior and secretory profile [13]. In
this respect, we have recently reported that DC exposure
to HIV-1 R5 gp120 resulted in production of IL-6 via
MAPK/NF-kB pathways which, in turn, activated STAT3
by an autocrine loop [14]. This modulation is dependent
on C-C chemokine receptor 5 (CCR5), the principal core-
ceptor of HIV-1 entry in DC, and it is specific for gp120,
since the C-C chemokine ligand 4 (CCL4), the most spe-
cific natural ligand for CCR5, did not induce IL-6 produc-
tion and STAT3 activation in these cells [14].
Interestingly, a growing body of evidence demonstrates
that miRs are closely associated with the STAT3 signal-
ing pathway supporting the existence of regulatory feed-
back loops between miRs and several components of the
STAT3 pathway in different cancer contexts [15].
In this study, we performed a bioinformatics analysis
to identify a panel of miRs that present one or more
STAT3 binding sites in their promoter region. Moreover,
we selected miR targeting genes belonging to STAT3 sig-
naling pathway and determined whether the addition of
gp120 to monocyte- derived DCs (MDDCs) would alter
their expression levels. We found that gp120-triggered
STAT3 activation directly influenced the expression of
miR-21, miR-181b and miR-155. Bioinformatics analysis
of miR putative targets unraveled that these genes
mainly belong to biological process related to ‘transcrip-
tion’ in a complex network of interactions relevant to
HIV-DC biology. Finally, we validated a selection of pu-
tatively regulated proteins and we showed that the ex-
pression of gp120-deregulated miRs is in agreement with
the abundance of their target proteins (i.e., PIAS3 and
STAT1).
Results
Promoters of precursor miRs contain several predicted
STAT3 binding sites
We have recently reported that exposure of MDDCs to
R5 gp120 activates the STAT3/IL-6 axis [14]. STAT3 has
been predicted to regulate the transcription of a great
number of miRs and putative STAT3 binding sites were
identified in many miR promoters [16, 17]. Starting from
these data, we generated a list of miRs that was then
used to predict the number of putative STAT3 binding
sites. Table 1 shows the result of this prediction by
which the number of putative STAT3 binding sites
employing the matrix-derived models (JASPAR CORE
and TRANSFAC models) and three different STAT3
binding motifs (MA0144.1, M00225 and M00497) have
been obtained. Information on position, strand, score
value and statistical significance of the predicted STAT3
binding sites are reported in additional file 1.
To select miRs specifically related to STAT3 biological
processes and directly implicated in the regulation of
STAT3 signaling pathway activated in gp120-exposed
MDDCs [14], the same miR list was intersected with the
group of validated miRs annotated in the miRWalk data-
base whose targets belong to STAT3 signaling pathway.
This analysis led to a restricted list of 14 miRs poten-
tially regulated by STAT3 and targeting genes annotated
in the STAT3 signaling pathway (Biocarta) that is shown
in Table 2. Detailed information on this analysis is pro-
vided in additional file 2. Interestingly, some of the miRs
reported in Table 2 (i.e., miR-21, miR-125b, miR-135b,
miR-181b and miR-155) were already predicted to be
regulated by STAT3 and also experimentally validated
[16, 18–21].
HIV-1 gp120-induced activation of STAT3 modulates miR
expression profiles in MDDCs
On the basis of the bioinformatics analyses illustrated
above, we first experimentally validated a panel of miRs
including miR-21, miR-125b, miR-135b and miR-181b in
gp120-treated MDDCs by real-time quantitative PCR
(qPCR). As shown in Fig. 1, miR-21 (A) and miR-181b
(B) were down- and up-regulated, respectively, in cells
treated with R5 gp120 at 18 h. Conversely, no significant
difference was observed at 6 h. Likewise, gp120 treat-
ment did not result in any significant modulation of
miR-125b, whereas miR-135b did not amplify (data not
shown). Although miR modulation was quite modest, it
showed reproducibility among all donors tested (n = 12)
and results were statistically significant with respect to
untreated controls. Then, to better define the role of
STAT3 in the gp120-induced modulation of miR-21 and
miR-181b, we assessed the expression profile of these
miRs in the presence of Stattic, a non-peptidic small
molecule inhibiting STAT3 activation and dimerization
[22]. Although the addition of Stattic did not per se
modulate the baseline expression levels of these miRs, it
completely abolished the gp120-induced down-modulation
of miR-21 (C) as well as the up-modulation of miR-181b
(D), thus confirming a role for STAT3 in the regulation of
these miRs in MDDCs.
HIV-1 gp120 and LPS have been reported to induce,
at some extent, overlapping effects in a variety of cell
types, as both molecules promote cytokine/chemokine
secretion and modulate cell activation state. Furthermore,
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Table 1 Analysis of the promoter regions of putative STAT3 regulated miRs
Number of predicted STAT3 binding sites
MA0144.1 M00225 M00497 Total
hsa-mir-3124 8 12 5 25
hsa-mir-92b 6 12 4 22
hsa-mir-1205 11 4 6 21
hsa-mir-1206 7 12 1 20
hsa-mir-1256 9 8 2 19
hsa-mir-629 4 11 4 19
hsa-mir-146a 2 5 12 19
hsa-mir-3125 10 7 1 18
hsa-mir-1255a 10 6 2 18
hsa-mir-3142 9 7 2 18
hsa-mir-125b-2 8 8 2 18
hsa-mir-155 8 5 4 17
hsa-mir-30e 8 3 5 16
hsa-mir-645 11 2 3 16
hsa-mir-181b-1 6 3 7 16
hsa-mir-1537 9 4 2 15
hsa-mir-3197 6 7 2 15
hsa-mir-21 7 4 4 15
hsa-mir-30c-1 12 1 2 15
hsa-mir-1825 12 0 2 14
hsa-mir-29a 8 2 3 13
hsa-mir-135b 7 2 4 13
hsa-mir-1207 7 2 3 12
hsa-mir-619 6 2 4 12
hsa-mir-548h-1 4 1 7 12
hsa-mir-646 5 4 3 12
hsa-let-7b 8 3 1 12
hsa-mir-125b-1 3 4 5 12
hsa-mir-181a-2 10 1 1 12
hsa-mir-29b-1 5 2 3 10
hsa-mir-3145 3 5 1 9
hsa-mir-612 5 4 0 9
hsa-mir-3174 4 3 2 9
hsa-mir-630 2 4 3 9
hsa-mir-451 8 1 0 9
hsa-mir-29c 6 1 1 8
hsa-mir-202 5 1 1 7
hsa-mir-148b 2 2 3 7
hsa-mir-181b-2 4 3 0 7
hsa-let-7a-3 5 1 0 6
hsa-mir-548c 0 0 2 2
The number of STAT3 binding site for each sequence motif obtained by LASAGNA search is reported for each selected miR
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MDDCs activated by LPS show a typical miR expression
profile that includes a remarkable up-modulation of miR-
155 and to a lesser extent, of miR-146 [23–26]. Of note,
both miRs have been reported to play an important role in
the modulation of the immune response [23, 27]. As
shown in Fig. 2, while LPS markedly up-modulated miR-
155 and miR-146 expression, at early time points (6 h),
gp120 exhibited a significant inhibitory effect (1.4 fold de-
crease) on miR-155 that disappeared at later time points
(18 h), while miR-146 was not affected.
In keeping with our previous observation that CCL4
does not affect the STAT3/IL-6 axis [14], this chemo-
kine, known as the most specific natural ligand engaging
CCR5, did not alter the expression of miR-21, miR-155
and miR-181b expression, as well as that of miR-146
(Table 3).
Gene Ontology of miR-21, miR-155 and miR-181b predicted
targets
On the basis of the results on the experimental valid-
ation of gp120-modulated miRs in MDDCs, we inte-
grated the initial target prediction analysis (Table 2) by
using our previously published procedure [28] that
exploits the predictions of three different algorithms
(TargetScan, MiRanda and Pita; Additional file 3). By
this in-house R bioconductor script we obtained the
combined list of unique predictions for miR-21, miR-155
and miR-181b. The complete list of target genes for each
of these three gp120-modulated miRs is reported in
Additional file 4. We found that miR-21, miR-155 and
miR-181b targeted 1119, 1468 and 2617 genes, respectively.
To identify the genes targeted by more than one miR, we
Fig. 1 Real-time qPCR of HIV gp120 modulated miRs. Cells were treated with gp120 for 6–18 h or left untreated in the presence or in the absence of
Stattic (10 μM, 1 h of pretreatment) and total RNA was extracted, reverse transcribed and subjected to Real-time qPCR. Relative fold of change of ex-
pression of miR-21 a-c, miR-181b (B-D), in gp120 stimulated MDDCs against untreated controls were calculated using the comparative Ct (2-ΔΔCt)
method. PCR were run in triplicate and the mean of 12 (A-B) or 5 c-d independent experiments ± SE is shown. p values were calculated by ANOVA
and statistical significance is indicated vs untreated control
Table 2 List of genes in the STAT3 signaling pathway targeted
by STAT3 regulated miR
miRNA name Targeted genes in STAT3 signaling pathway
hsa-mir-21 MAPK3, FRAP1, STAT3
hsa-mir-155 STAT3, MAPK3, JAK2, JAK1, FRAP1
hsa-let-7b STAT3, MAPK3, JAK2
hsa-let-7a-3 STAT3, MAPK3, JAK2
hsa-mir-146a STAT3, MAPK3
hsa-mir-125b-2 MAPK3, FRAP1, STAT3
hsa-mir-125b-1 MAPK3, FRAP1, STAT3
hsa-mir-29a FRAP1, MAPK3
hsa-mir-135b STAT3
hsa-mir-451 JAK2, FRAP1
hsa-mir-30c-1 JAK2
hsa-mir-181a-2 MAPK3
hsa-mir-181b-2 STAT3
hsa-mir-181b-1 STAT3
The table shows the genes present in the STAT3 signaling pathway (Biocarta)
that are validated targets of a selection of STAT3 regulated miR
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calculated the intersections among the three lists and rep-
resented them using Venn diagrams (Fig. 3). Interestingly,
79 genes were targeted by all miRs (Additional file 5).
Information concerning the putative binding sites are pro-
vided in Additional file 6.
MiRs can regulate many target genes and modulate
multiple pathways at the same time. To determine the
biological processes and signaling pathways implicated
in gp120-induced effects in MDDCs, the predicted tar-
gets of the newly identified gp120 deregulated miRs were
separately subjected to gene ontology and KEGG path-
way enrichment analysis, and annotated by means of
DAVID bioinformatics tool [29]. Remarkably, the most
significant (p < 0.05) categories of biological processes
identified for miR-155 and miR-181b were transcription,
regulation of transcription, regulation of RNA metabolic
process, DNA-dependent regulation of transcription
(Table 4). No statistically significant biological processes
resulted for miR-21 targets, most probably due to the
highly stringent selection criteria of the algorithm used
(see additional file 3). By taking the combined list of
unique predictions for miR-21, miR-155 and miR-181b,
the bioinformatics analysis outlined the term ‘regulation of
transcription’ as the biological process with the highest
number of annotated targets (772 genes) (Table 4). As ex-
pected, many transcripts annotated in the JAK/STAT sig-
naling pathway, including STAT members (STAT1 and
STAT3), STAT regulatory factors (PIAS3 and SOCS),
MAPK family members such as MAPK1 (ERK2), MAP2K1
(MEK1), MAP2K4 (MEK4), MAP3K1 (MEKK1), apoptosis
Fig. 2 Real-time qPCR of miR-155 and miR-146. Cells were treated, and
relative FC of expression of miR-155 a and miR-146 b in gp120- or
LPS- stimulated MDDCs against untreated controls were calculated
as described in Fig. 1. PCR were run in triplicate and the mean of 8
independent experiments ± SE is shown. p values were calculated
by ANOVA and statistical significance is indicated vs
untreated control
Table 3 Effects of CCL4 on miR-21, miR-146, miR-155 and
miR-181b
Control CCL4 (6 h) CCL4 (18 h) p-value
miR-21 1 0.80 ± 0.31 0.80 ± 0.36 0.642
miR-146 1 1.10 ± 0.29 1.38 ± 0.23 0.347
miR-155 1 1.15 ± 0.69 1.11 ± 0.06 0.932
miR-181b 1 1.31 ± 0.38 1.51 ± 0.21 0.277
Fold changes and standard errors of miR-21, miR-146, miR-155 and miR-181b
expressed in DCs after CCL4 treatment (6 and 18 h). p values were calculated
by ANOVA and statistical significance is indicated vs untreated control (n = 5)
Fig. 3 Overlap of predicted genes targeted by STAT3-regulated
miRs. Venn diagram showing the overlap between predicted target
genes of miR-155 (red circle), miR-181b (green circle) and miR-21
(blue circle). The numbers in the intersections represent the number
of target genes (390, 259 and 136) targeted by two miRs (miR-155 and
miR-181b, miR-181b and miR-21 and miR-21 and miR-155, respectively)
or by all of them (79 genes). The majority of genes (863 for miR-155,
1889 for miR-181b and 645 for miR-21) are targeted by only one miR
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mediators as well as cytokines and cytokine receptors (e.g.
IL12A, IFNγ, CCR5, IL-1β) were found in this biological
process. Furthermore, many of these genes belonged to
more than one pathway, and were targeted by more than
one miRs. Fig. 4 shows the network of interactions, which
may be deregulated upon exposure of MDDCs to gp120 as
a consequence of the altered expression of target genes,
resulting from deregulation of miR-21, miR-155 and miR-
181b. This network included cell growth, proliferation, fate
determination, and development, immunity, pro-
inflammatory effects and apoptosis pathways. As shown in
Fig. 4, bioinformatics prediction outlined the presence of a
huge number of potential targets for the three miRs, whose
functional validation (i.e., protein expression) in our experi-
mental model would require demanding and expensive
analysis. Thus, to overcome these issues, we refined data
by selecting a panel of genes targeted by one or more
gp120 deregulated miR belonging to the signaling cascade
previously reported to be altered in gp120-exposed
MDDCs [14, 30, 31]. Among various targets, we analyzed
the expression level of genes belonging to the JAK/STAT
signaling pathway (i.e. STAT1, STAT2, STAT3, JAK2,
PIAS3, SOCS1, SOCS3), MAPK/NF-kB signaling pathway
(i.e. p38, ERK, JNK, p50, p65, IkBα, IKKβ), and apoptosis
(AKT, BcL2, BCLxL, PKR), by western blotting analysis, in
gp120-exposed MDDCs. As shown in Fig. 5, the results of
protein expression analysis already reported in our previ-
ous study (STAT1, STAT2, STAT3, PIAS3, SOCS3, p38,
p65, IkBα) or de novo carried out on the basis of bioinfor-
matics analysis (ERK, JNK, p50, IKKβ, JAK2, SOCS1, AKT,
BcL2, BCLxL, PKR) clearly indicate that among the puta-
tive targets analyzed, only PIAS3 and STAT1 protein ex-
pression levels are modulated, suggesting the involvement
of gp120-deregulated miRs.
Table 4 Gene Ontology analysis for STAT3-deregulated miRNA (combined and individual predictions)
Gene
Ontology ID
Gene Ontology Term No. of
genes
% p-value Corrected p-value
(FDR)
Target genes for miR-155
GO:0006350 transcription 246 16.8 1.06E-11 1.93E-08
GO:0045449 regulation of transcription 288 19.7 6.23E-11 1.13E-07
GO:0051252 regulation of RNA metabolic process 201 13.8 1.30E-07 2.35E-04
GO:0006355 regulation of transcription, DNA-dependent 197 13.5 1.57E-07 2.85E-04
Target genes for miR-181b
GO:0045449 regulation of transcription 488 18.7 7.49E-13 1.40E-09
GO:0006350 transcription 406 15.6 2.00E-12 3.75E-09
GO:0051252 regulation of RNA metabolic process 345 13.2 1.05E-09 1.97E-06
GO:0006355 regulation of transcription, DNA-dependent 338 13.0 1.32E-09 2.47E-06
Combined target genes for miR-21, miR-155 and miR-181b
GO:0006350 transcription 647 15.3 1.13E-19 2.15E-16
GO:0045449 regulation of transcription 772 18.2 4.94E-19 9.40E-16
GO:0051252 regulation of RNA metabolic process 539 12.7 9.54E-13 1.82E-09
GO:0006355 regulation of transcription, DNA-dependent 527 12.4 1.92E-12 3.66E-09
GO:0016481 negative regulation of transcription 154 3.6 1.88E-07 3.57E-04
GO:0010629 negative regulation of gene expression 166 3.9 2.28E-07 4.34E-04
GO:0045934 negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid
metabolic process
163 3.8 3.00E-06 5.72E-3
GO:0051172 negative regulation of nitrogen compound metabolic process 164 3.9 4.54E-06 8.64E-3
GO:0031327 negative regulation of cellular biosynthetic process 175 4.1 5.03E-06 9.57E-3
GO:0010558 negative regulation of macromolecule biosynthetic process 171 4.0 5.71E-06 1.09E-2
GO:0009890 negative regulation of biosynthetic process 176 4.2 1.29E-05 2.45E-2
GO:0000122 negative regulation of transcription from RNA polymerase II promoter 92 2.2 1.81E-05 3.45E-2
GO:0007167 enzyme linked receptor protein signaling pathway 113 2.7 1.97E-05 3.75E-2
GO:0006357 regulation of transcription from RNA polymerase II promoter 215 5.1 2.18E-05 4.16E-2
The table shows the Gene Onthology terms obtained after the bioinformatics analysis on the genes targeted by STAT3-regulated miRs, taken individually or
in combination
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Discussion
miRs play important roles in many biological processes,
including cellular defense against viral infection [32]. In-
creasing evidence has emerged that host miRs serve in
animal cells to restrict viral infections. In turn, many vi-
ruses evolved strategies to counteract miRs action and
may encode their own miRs [33]. In HIV-1 infection,
many mechanisms underlying the capacity of the virus
to induce immune destruction have been elucidated.
However, the important role that miRs play in HIV-1
pathogenesis is only now emerging [9].
Studies carried out in PBMC highlighted the importance
of the RNA interference machinery in HIV infection, in
regulating viral replication [34] and latency [35, 36] as well
as in defining different stages of disease [37]. Likewise, in
monocytes/macrophages the differential expression of
some miRs has been associated with susceptibility to
infection [38]. Conversely, few studies have so far ad-
dressed the question of whether HIV-1 products may play
a role in miRs modulation in the absence of productive in-
fection. In this respect, Orecchini and co-workers re-
ported a direct involvement of Tat, ectopically expressed,
in the up-modulation of miR-222 [39]. Likewise, miR ex-
pression analysis carried out by Bignami and colleagues in
healthy CD4+ T cells exposed to gp120 in vitro, outlined
that miRs profile could be not only the result of a product-
ive infection but also of exposure to HIV products that
leave a signature in immune cells [37].
In keeping with these observations, and based on the
identification of STAT3 binding motifs in the promoter
region of a panel of selected miRs, we experimentally
validated that MDDCs treated with gp120, show a
down-regulation of miR-21 and miR-155 expression,
whereas miR-181b is up-regulated at late time points.
Interestingly, CCR5 engagement by one of its most spe-
cific ligand (i.e., CCL4) does not induce any change in
the expression of these miRs, adding further evidence
that the interaction of HIV-1 gp120 with CCR5 evokes
Fig. 4 Interaction network of gp120-deregulated miRs and predicted targets in HIV gp120 exposed MDDCs. Many different pathways (JAK-STAT
signaling, MAPK signaling, PI3k-Akt signaling, NF-kB signaling, apoptosis, and cytokine-cytokine receptor interaction) have been joined into a uni-
fied network of interactions, representing genes potentially involved in DC response to gp120. Three different colored dots were placed next to
genes to indicate the putative targeting by miR-155 (red dot), miR-181b (green dot) or miR-21 (blue dot). *Not listed as predicted target but ex-
perimentally validated [65]
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complex and distinct signaling responses, differing from
those activated by the coreceptors’ chemokine ligands
[14, 40–46]. A growing body of evidence demonstrates
that STAT3 signaling pathway is closely associated with
the transcriptional regulation of some miRs including
miR-21 and miR-181b [19, 47] as well as miR-155 [16, 18].
In keeping with these observations, we showed a striking
direct relationship between STAT3 activation and expres-
sion of miR-21 and miR-181b since the gp120-induced de-
regulation of both miRs is completely reverted in the
presence of Stattic. The time-course observed for the
gp120-induced miR modulation support the hypothesis
that late STAT3 activation via IL-6 production is respon-
sible for this event as at earlier time points (6 h) we did
not observe any changes in miRs expression. Several stud-
ies independently support the hypothesis of regulatory cir-
cuits between miR and STAT3 pathway in different cancer
contexts linked to inflammation as a key component fa-
voring tumorigenesis [15]. Of note, the miR we found
concomitantly deregulated in DC upon exposure to gp120
have been previously reported to belong to a regulatory
loop contributing to STAT3-mediated cancer develop-
ment [15].
To the best of our knowledge, this is the first demon-
stration of HIV-induced miR modulation in human
MDDCs. miRs are important regulators of DC differenti-
ation and activation [27] and increased expression of
miR-155 and miR-21 in DCs represents a general fea-
tures associated with cell activation [24, 48]. Our finding
that miR-21 and miR-155 are downregulated by gp120
together with our previous report that gp120 induces a
tolerogenic-like DC phenotype [49] suggests that these
HIV-modulated miRs could play a role in viral-induced
DC dysfunction. In this regards, independent studies
correlated miR-155 expression with HIV infectivity and
spreading. In particular, Martinez-Nunez and colleagues
demonstrated that increased expression of miR-155 cor-
relates with reduced levels of DC-SIGN expression thus
limiting gp120 binding to DCs [50]. Likewise, Napuri
and co-workers highlighted a synergy between HIV-1
and cocaine to lower miR-155 and miR-20a in MDDCs
that modulates DC-SIGN expression, DC maturation,
and HIV infectivity [51]. Finally, silencing of miR-155 in
murine DCs is associated with reduced production of
IL-12 [52].
Moreover, gp120-deregulated miRs in MDDCs have
been found to be concomitantly regulated in different
experimental settings [53, 54], and reported to regulate
important biological processes relevant to DC-HIV inter-
action, including NF-kB signaling pathway [19, 55, 56],
DC maturation [23, 24, 48, 50], inflammation [56–58] and
HIV replication [53]. By using a bioinformatics pipeline
intersecting the predictions of three different algorithms
[28], we identified ‘regulation of transcription’ as one of
the most significantly enriched biological process for these
miRs. Interestingly, among the overall list of miR targets,
we found many genes related to the JAK/STAT signaling
pathway, STAT regulatory factors, NF-kB/MAPK family
Fig. 5 HIV gp120 up-regulates PIAS3 and STAT1 protein expression in MDDCs. MDDCs were stimulated with gp120 (5 μg/ml) for 18 h. Cell lysates
were resolved by 8-12 % SDS-PAGE, transferred to a nitrocellulose membrane, and subjected to immunoblot analysis with antibodies specific for:
p38, ERK1/2, JNK, p65, p50, IkBα, IKKβ, JAK2, STAT-1, −2, −3, SOCS-1, −3, PIAS3, Bcl2, BCLxL, Akt, and PKR. Data from one representative experiment
are shown. a Graphs show the level of protein as determined by densitometry (ImageJ software) and calculated relatively to untreated control
(C), where each sample was normalized to total actin. The average fold from two-four independent experiments was represented, along with the
SD. b Immunoblot analysis with antibodies specific for PIAS3 and STAT1. Actin expression is shown as gel loading control. Values below the lanes
show band intensities of the respective bands, normalized to actin expression. Data from one representative experiment out of four analyzed
are shown
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members among others (Fig. 4). Several potential targets
have been experimentally validated by assessing protein
expression in MDDCs exposed to gp120. However, only
two genes, that we previously reported to be regulated by
gp120, i.e. STAT1 and PIAS3 were found to be modulated
at the protein level. Although the observation that STAT3
activation is maintained despite the persistent PIAS3 up-
regulation may at first glance appear contradictory, previ-
ous studies reported that STAT3 activation and high levels
of inhibitory molecules co-exist up to several hours fol-
lowing stimulation [59]. Overall, this suggests that despite
PIAS3 overexpression, its inhibitory function on STAT3
activation might be altered in the presence of gp120 thus
contributing to chronic immune activation. Furthermore,
it is also worth to be considered that although STAT3 pro-
tein levels are not modulated by gp120, the levels of
STAT1 are increased at late time points. In this regard, it
has been reported that STAT1 and STAT3 balanced ex-
pression or phosphorylation levels may somehow regulate
the extent of inflammation [60].
Conclusions
The new data provided by the present study add further
complexity to the model we previously postulated to de-
scribe the interaction between DCs and HIV-1 in the ab-
sence of productive infection. As shown in Fig. 6, gp120
triggers a cascade of signaling events initiated by early
activation of STAT3 leading to IL-6 production. Subse-
quently, IL-6 determines a second round of STAT3
activation responsible for miR regulation. Although it re-
mains to be demonstrated that miR deregulation directly
impact the function of molecular components belonging
to STAT3 signaling, we exclude that these miRs directly
regulate STAT3 expression as identical levels of protein
are found independently of gp120 exposure of DC.
Conversely, our data suggests that miRs could indirectly
act on key regulators of STAT3/IL-6 axis ultimately
contributing to the chronic immune activation observed
in AIDS.
Overall, this study provides new evidence for the mo-
lecular mechanisms and signaling pathways triggered by
HIV-1 in DCs, emphasizing the role of network interac-
tions rather than individual connections among signaling
components, transcription factors, miRs and their pre-
dicted targets in this process. Due to the complexity of
these regulatory networks, large scale studies and com-
prehensive analyses are therefore needed to validate the
role of these miRs in HIV infection, and determine the
effect of their selective targeting in disease phenotype
and outcome. Taken together experimental and bioinfor-
matics analyses support the hypothesis that the STAT3-
regulated miRs validated in our study may have a role in
Fig. 6 Schematic model of gp120-induced signalling pathways in MDDCs. The cascade of signals triggered by R5 HIV-1 gp120 in MDDCs is
schematically shown
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the DC response to HIV. In this scenario, the determin-
ation of STAT3-dependent miR deregulation, their hypo-
thetical targets and interaction network may provide a
broader view of the host-virus interactions.
Methods
Ethics statements
Healthy donor buffy coats were obtained from Centro
Trasfusionale University of Rome’Sapienza”. Buffy coats
were not obtained specifically for this study. Informed
consent has not been asked because data were analyzed
anonymously. Data from healthy donors have been
treated by Centro Trasfusionale according to the Italian
law on personal data management “Codice in materia di
protezione dei dati personali” (Testo unico D.L. June 30,
2003 n. 196).
Reagents
All culture reagents were purchased from Biowhittaker
as endotoxin-free lots. Ultra pure LPS from E. Coli
(serotype EH100, Ra TLRgrade) was purchased from
Alexis Biochemicals (Nottingham, UK). Recombinant
gp120 from CN54 HIV-1 strain was obtained from the
national AIDS Research and Reference Reagent Program
(Bethesda, MD). Recombinant CCL4 was purchased
from R&D Systems. To test the effect of Stattic (Sigma,
St Louis, MO), cells were treated prior to and during
gp120 exposure with the inhibitor. Stattic did not exhibit
any toxicity at the used concentration, as assessed by
MTT assay (data not shown).
Cell separation and culture
Monocytes were isolated from PBMCs obtained from
healthy donor buffy coats by immunomagnetic selection
using CD14 microbeads (MACS monocyte isolation kit
from MiltenyiBiotec, Auburn, CA), according to the
manufacturer’s instructions. This procedure yields a pure
(≥98 %) population of monocytes, as assessed by FACS
analysis of lineage specific surface markers (CD1a,
CD14, CD3, CD19, CD56). To obtain immature
MDDCs, monocytes were cultured at 1 x 106 cells/ml in
RPMI 1640 medium (Life Technologies, Gaithersburg,
MD) containing 10 % FBS in the presence of GM-CSF
(50 ng/ml) and IL-4 (500 U/ml). Cytokines were added
to the cultures every 3 days. Both cytokines were kindly
provided by Schering-Plough (Dardilly, France). On day
6, MDDCs were stimulated with LPS (10 ng/ml), gp120
(5 μg/ml), or CCL4 (100nM).
Prediction of transcription factor binding sites
To predict the putative STAT3 binding sites on precur-
sor region upstream of the miRNA sequence, we consid-
ered the list of miRNAs predicted to have putative
STAT3 binding sites which has been recently reported
[16, 17]. Since for most of these miRNAs the putative
binding region spanned several kilobases from the tran-
scription start site, the calculated binding score ranged
from 100 to 1000 and most of them have a quite low
STAT3 binding score (<500), we decided to refine the
analysis by considering only those miRNAs with a higher
STAT3 binding score (>500) and by limiting the prediction
to a region of 3000 bases upstream the miRNA sequence.
For these miRNAs, the upstream sequences were extracted
by the University of California Santa Cruz genome browser
(UCSC) (https://genome.ucsc.edu/). These sequences were
then used to identify the STAT3 binding motif using the
LASAGNA-search software (http://biogrid-head.engr.u-
conn.edu/lasagna_search/) as previously described [61].
miRNA targets and STAT3 signaling pathway
Validated interactions among miRNAs and target genes
belonging to STAT3 signaling pathway (Biocarta) were
obtained by the curated database miRWalk (http://
www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) as pre-
viously described [62].
Gene ontology and pathways analysis
To determine the biological processes and signaling path-
ways in which the predicted targets of the deregulated
miRs were involved, we performed Gene Ontology, KEGG
pathway enrichment analysis and annotation by means of
DAVID bioinformatics tool [29].
Expression of miRNAs
The expression of miRNAs were assessed by quantitative
PCR (qPCR). Total RNA was extracted with the Total
RNA Purification Plus Kit (Norgen Biotek, Canada) and
converted into cDNA by using specific stem-loop
primers [63]. The endogenous control let-7a was chosen
as the endogenous miR since it displayed more constant
expression values among all treatments with respect to
U6 (data not shown). Relative quantification was per-
formed by using the comparative Ct method [64]. qPCR
was performed on an ABI-Prism 7900 HT (Lifetechnolo-
gies, Foster City, CA) using the SensiMix dT master mix
(Bioline, London, UK), according to the manufacturer’s
instructions.
Immunoblotting
MDDCs were stimulated with gp120 (5 μg/ml) for 18 h.
Cell were lysed in RIPA buffer (150 mM NaCl, 50 mM
Tris-Cl (pH 7.5), 1 % Nonidet P-40, 0.5 % sodium deoxy-
cholate, and 0.1 % SDS) containing a cocktail of protease
and phosphatase inhibitors and protein extracts were re-
solved by 8-12 % SDS-PAGE, transferred to a nitrocellulose
membrane, and subjected to immunoblot analysis with
antibodies specific for STAT-1, STAT −3, SOCS1, NF-kB
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p50, IkBα, IKKβ, p38, ERK1/2, JNK, Akt and PIAS3 (Cell
Signaling Technology; catalog numbers: 9172, 9139, 3950,
3035, 9242, 2684, 9212, 9102, 9252, 9272, 9042), and
SOCS3, JAK2, STAT-2, NF-kB p65, Bcl2, BCLxL and PKR
(Santa Cruz; catalog numbers: sc51699, sc476, sc81334,
sc509, sc634, sc634, sc707), and actin (BD Transduction
Laboratories; catalog numbers: 612656). Levels proteins
were quantified using ImageJ software (software devel-
oped by Wayne Rasband, National Institutes of Health,
Bethesda, MD).
Statistical analysis
Statistical comparison between various groups was per-
formed by Student’s t-test or one way analysis of variance
(ANOVA) with either least significant difference (LSD) or
Bonferroni post hoc tests as appropriate, using the SPSS
software (12.0.2). Comparisons were made between means
from several experiments. Differences were considered
significant when p values were < 0.05. Statistical signifi-
cance is indicated with * for p < 0.05.
Deposition of data
Not applicable
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each STAT3-regulated miRs with a binding score > 500.
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